Florey Institute of Neuroscience and Mental Health, Parkville, 3052 Victoria, Australia, and.
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, 3052 Victoria, Australia.
J Neurosci. 2019 Nov 27;39(48):9521-9531. doi: 10.1523/JNEUROSCI.1160-19.2019. Epub 2019 Oct 22.
Human pluripotent stem cells (hPSCs) are a promising resource for the replacement of degenerated ventral midbrain dopaminergic (vmDA) neurons in Parkinson's disease. Despite recent advances in protocols for the generation of vmDA neurons, the asynchronous and heterogeneous nature of the differentiations results in transplants of surprisingly low vmDA neuron purity. As the field advances toward the clinic, it will be optimal, if not essential, to remove poorly specified and potentially proliferative cells from donor preparations to ensure safety and predictable efficacy. Here, we use two novel hPSC knock-in reporter lines expressing GFP under the LMX1A and PITX3 promoters, to selectively isolate vm progenitors and DA precursors, respectively. For each cell line, unsorted, GFP, and GFP cells were transplanted into male or female Parkinsonian rodents. Only rats receiving unsorted cells, LMX1A-eGFP, or PITX3-eGFP cell grafts showed improved motor function over 6 months. Postmortem analysis revealed small grafts from PITX3-eGFP cells, suggesting that these DA precursors were not compatible with cell survival and integration. In contrast, LMX1A-eGFP grafts were highly enriched for vmDA neurons, and importantly excluded expansive proliferative populations and serotonergic neurons. These LMX1A-eGFP progenitor grafts accelerated behavioral recovery and innervated developmentally appropriate forebrain targets, whereas LMX1A-eGFP cell grafts failed to restore motor deficits, supported by increased fiber growth into nondopaminergic target nuclei. This is the first study to use an hPSC-derived reporter line to purify vm progenitors, resulting in improved safety, predictability of the graft composition, and enhanced motor function. Clinical trials have shown functional integration of transplanted fetal-derived dopamine progenitors in Parkinson's disease. Human pluripotent stem cell (hPSC)-derived midbrain progenitors are now being tested as an alternative cell source; however, despite current differentiation protocols generating >80% correctly specified cells for implantation, resultant grafts contain a small fraction of dopamine neurons. Cell-sorting approaches, to select for correctly patterned cells before implantation, are being explored yet have been suboptimal to date. This study provides the first evidence of using 2 hPSC reporter lines (LMX1A-GFP and PITX3-GFP) to isolate correctly specified cells for transplantation. We show LMX1A-GFP, but not PITX3-GFP, cell grafts are more predictable, with smaller grafts, enriched in dopamine neurons, showing appropriate integration and accelerated functional recovery in Parkinsonian rats.
人类多能干细胞(hPSCs)是替代帕金森病中退化的腹侧中脑多巴胺能(vmDA)神经元的有前途的资源。尽管最近在生成 vmDA 神经元的方案方面取得了进展,但分化的异步和异质性导致移植的 vmDA 神经元纯度出乎意料地低。随着该领域向临床推进,如果不是必需的,从供体制备物中去除不良指定和潜在增殖细胞将是最佳选择,以确保安全性和可预测的疗效。在这里,我们使用两种新型 hPSC 敲入报告基因系,分别在 LMX1A 和 PITX3 启动子下表达 GFP,以分别选择性地分离 vm 祖细胞和 DA 前体细胞。对于每条细胞系,未分选、GFP 和 GFP 细胞均被移植到雄性或雌性帕金森病啮齿动物中。只有接受未分选细胞、LMX1A-eGFP 或 PITX3-eGFP 细胞移植物的大鼠在 6 个月后表现出运动功能改善。死后分析显示,来自 PITX3-eGFP 细胞的小移植物,表明这些 DA 前体细胞与细胞存活和整合不兼容。相比之下,LMX1A-eGFP 移植物高度富集 vmDA 神经元,并且重要的是排除了扩张性增殖群体和 5-羟色胺能神经元。这些 LMX1A-eGFP 祖细胞移植物加速了行为恢复,并使发育适当的前脑靶标神经支配,而 LMX1A-eGFP 细胞移植物未能恢复运动缺陷,这得到了纤维向非多巴胺靶核生长增加的支持。这是第一项使用 hPSC 衍生的报告基因系来纯化 vm 祖细胞的研究,从而提高了安全性、移植物组成的可预测性和运动功能。临床试验已经显示出在帕金森病中移植的胎儿衍生多巴胺前体细胞的功能整合。人类多能干细胞(hPSC)衍生的中脑祖细胞现在正在作为替代细胞来源进行测试;然而,尽管目前的分化方案为植入生成了>80%的正确指定细胞,但由此产生的移植物仅包含一小部分多巴胺神经元。目前正在探索在植入前选择正确模式化细胞的细胞分选方法,但迄今为止效果并不理想。本研究首次提供了使用 2 种 hPSC 报告基因系(LMX1A-GFP 和 PITX3-GFP)分离用于移植的正确指定细胞的证据。我们表明,LMX1A-GFP,但不是 PITX3-GFP,细胞移植物更具可预测性,较小的移植物富含多巴胺神经元,在帕金森病大鼠中表现出适当的整合和加速的功能恢复。